INTS vs. PLX, TARA, KYTX, NMRA, SGMO, IVVD, EXOZ, CABA, CRDL, and CCCC
Should you be buying Intensity Therapeutics, Inc. Common stock stock or one of its competitors? The main competitors of Intensity Therapeutics, Inc. Common stock include Protalix BioTherapeutics (PLX), Protara Therapeutics (TARA), Kyverna Therapeutics (KYTX), Neumora Therapeutics (NMRA), Sangamo Therapeutics (SGMO), Invivyd (IVVD), Exozymes (EXOZ), Cabaletta Bio (CABA), Cardiol Therapeutics (CRDL), and C4 Therapeutics (CCCC). These companies are all part of the "biological products, except diagnostic" industry.
Intensity Therapeutics, Inc. Common stock vs. Its Competitors
Protalix BioTherapeutics (NYSE:PLX) and Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, community ranking and risk.
In the previous week, Intensity Therapeutics, Inc. Common stock had 6 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 6 mentions for Intensity Therapeutics, Inc. Common stock and 0 mentions for Protalix BioTherapeutics. Intensity Therapeutics, Inc. Common stock's average media sentiment score of 1.89 beat Protalix BioTherapeutics' score of 0.00 indicating that Intensity Therapeutics, Inc. Common stock is being referred to more favorably in the news media.
Protalix BioTherapeutics has a beta of -0.21, suggesting that its stock price is 121% less volatile than the S&P 500. Comparatively, Intensity Therapeutics, Inc. Common stock has a beta of 4.03, suggesting that its stock price is 303% more volatile than the S&P 500.
16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 3.7% of Intensity Therapeutics, Inc. Common stock shares are owned by institutional investors. 6.5% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 18.6% of Intensity Therapeutics, Inc. Common stock shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Protalix BioTherapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 906.71%. Intensity Therapeutics, Inc. Common stock has a consensus target price of $8.50, suggesting a potential upside of 2,607.01%. Given Intensity Therapeutics, Inc. Common stock's higher possible upside, analysts plainly believe Intensity Therapeutics, Inc. Common stock is more favorable than Protalix BioTherapeutics.
Protalix BioTherapeutics has higher revenue and earnings than Intensity Therapeutics, Inc. Common stock. Intensity Therapeutics, Inc. Common stock is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
Protalix BioTherapeutics received 3 more outperform votes than Intensity Therapeutics, Inc. Common stock when rated by MarketBeat users. However, 90.91% of users gave Intensity Therapeutics, Inc. Common stock an outperform vote while only 81.25% of users gave Protalix BioTherapeutics an outperform vote.
Intensity Therapeutics, Inc. Common stock has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Intensity Therapeutics, Inc. Common stock's return on equity.
Summary
Intensity Therapeutics, Inc. Common stock beats Protalix BioTherapeutics on 9 of the 17 factors compared between the two stocks.
Get Intensity Therapeutics, Inc. Common stock News Delivered to You Automatically
Sign up to receive the latest news and ratings for INTS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intensity Therapeutics, Inc. Common stock Competitors List
Related Companies and Tools
This page (NASDAQ:INTS) was last updated on 6/13/2025 by MarketBeat.com Staff
